Previous 10 | Next 10 |
BioXp™ system and RapidAMP™ cell-free DNA kit rapidly accelerate antibody discovery pipelines by addressing critical bottlenecks associated with lead candidate gene synthesis, cloning, and scale-up SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq:...
The following slide deck was published by Codex DNA, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Codex DNA, Inc. 2022 Q1 - Results - Earnings Call Presentation
Codex DNA, Inc. (DNAY) Q1 2022 Earnings Conference Call May 10, 2022 16:30 ET Company Participants Richard Lepke - Director, Investor Relations Todd Nelson - Chief Executive Officer Jennifer McNealey - Chief Financial Officer Conference Call Participants Brandon Couillard - Jefferies Paul Kni...
Image source: The Motley Fool. Codex DNA, Inc. (NASDAQ: DNAY) Q1 2022 Earnings Call May 10, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Codex DNA, Inc. (DNAY) Q1 2022 Earnings Call Transcript
SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the first quarter ended March 31, 2022. “In the first quarter of 2022, we delivered robust revenue growth ...
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its first quarter 2022 financial results on Tuesday, May 10, 2022, after the market closes. In conjunction with the rel...
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker lineup for presentations at the PEGS Boston Conference and Expo, which is being held on May 2-6, 2022. The company will be sho...
SAN DIEGO, April 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the completion of proof-of-concept demonstrations showing that its technology can be used effectively for encoding digital data in DNA seq...
SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker presentation for the World Vaccine Congress Washington 2022, which is being held in Washington, DC. on April 18-21, 2022. The ...
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker lineup for presentations at SynBioBeta’s Built with Biology Global Conference, which is being held in Oakland, Ca...
News, Short Squeeze, Breakout and More Instantly...
Codex DNA Inc. Company Name:
DNAY Stock Symbol:
NASDAQ Market:
-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE N...
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction ...
SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company, today announced initiation of work under a collaboration to optimize the development and valid...